The risk or severity of adverse effects can be increased when Almotriptan is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorprothixene. The serum concentration of Bosutinib can be increased when it is combined with Flupentixol. Amantadine may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Nalbuphine is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Prazepam. Clarithromycin may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Articaine. The risk or severity of adverse effects can be increased when Flupentixol is combined with Fencamfamine. The risk or severity of adverse effects can be increased when Flupentixol is combined with Melatonin. Mefloquine may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclobenzaprine. The risk or severity of adverse effects can be increased when Flupentixol is combined with Fludiazepam. Sertraline may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Enflurane. The risk or severity of adverse effects can be increased when Eszopiclone is combined with Flupentixol. Tizanidine may increase the QTc-prolonging activities of Flupentixol. Sulfamethoxazole may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Pethidine is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Etoperidone. The risk or severity of adverse effects can be increased when Temazepam is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Quazepam. The serum concentration of Doxorubicin can be increased when it is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl loflazepate. Sulfisoxazole may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Alfentanil is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Carisoprodol. The risk or severity of adverse effects can be increased when Reserpine is combined with Flupentixol. Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. The risk or severity of adverse effects can be increased when Flupentixol is combined with Dextromoramide. The risk or severity of adverse effects can be increased when Flupentixol is combined with Olopatadine. The serum concentration of Prucalopride can be increased when it is combined with Flupentixol. Bortezomib may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Melperone. The risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenobarbital. Flupentixol may decrease the stimulatory activities of Phentermine. The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Dexbrompheniramine. The risk or severity of adverse effects can be increased when Flupentixol is combined with Alphaprodine. The risk or severity of adverse effects can be increased when Codeine is combined with Flupentixol. Buserelin may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Methapyrilene. The risk or severity of adverse effects can be increased when Flupentixol is combined with Stiripentol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Pipamperone. The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Tetrodotoxin. The risk or severity of adverse effects can be increased when Flupentixol is combined with Allopregnanolone. Foscarnet may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Adipiplon. The risk or severity of adverse effects can be increased when Selegiline is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Tiagabine. Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclizine. The risk or severity of adverse effects can be increased when Milnacipran is combined with Flupentixol. The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Fosphenytoin. The risk or severity of QTc prolongation can be increased when Sotalol is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Tetrahydropalmatine. Telavancin may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Ramelteon. The risk or severity of adverse effects can be increased when Flupentixol is combined with Zimelidine. Galantamine may increase the QTc-prolonging activities of Flupentixol. Sunitinib may increase the QTc-prolonging activities of Flupentixol. Doxepin may increase the QTc-prolonging activities of Flupentixol. Propafenone may increase the QTc-prolonging activities of Flupentixol. Vilanterol may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Methadyl Acetate. The risk or severity of adverse effects can be increased when Flupentixol is combined with Dextropropoxyphene. The therapeutic efficacy of Flupentixol can be decreased when used in combination with Levodopa. The risk or severity of adverse effects can be increased when Flupentixol is combined with Tandospirone. The risk or severity of adverse effects can be increased when Linezolid is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Scopolamine. The risk or severity of adverse effects can be increased when Citalopram is combined with Flupentixol. Flupentixol may increase the arrhythmogenic activities of Mequitazine. The risk or severity of adverse effects can be increased when Fentanyl is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Lurasidone. The risk or severity of adverse effects can be increased when Flupentixol is combined with Trans-2-Phenylcyclopropylamine. Lithium may increase the neurotoxic activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Gabapentin. The risk or severity of adverse effects can be increased when Flupentixol is combined with Halothane. The risk or severity of adverse effects can be increased when Flupentixol is combined with Proparacaine. The serum concentration of Everolimus can be increased when it is combined with Flupentixol. Gemifloxacin may increase the QTc-prolonging activities of Flupentixol. Octreotide may increase the QTc-prolonging activities of Flupentixol. Flupentixol may decrease the stimulatory activities of Mephedrone. The risk or severity of adverse effects can be increased when Flupentixol is combined with Dexmedetomidine. The risk or severity of adverse effects can be increased when Flupentixol is combined with Meclizine. Flupentixol may decrease the stimulatory activities of MMDA. The risk or severity of adverse effects can be increased when Flupentixol is combined with Etidocaine. Chloroquine may increase the QTc-prolonging activities of Flupentixol. The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Dronedarone. The risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydromorphine. The risk or severity of adverse effects can be increased when Flupentixol is combined with Dapiprazole. Flupentixol may increase the sedative activities of Metyrosine. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol. Diphenhydramine may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Oxymorphone. The risk or severity of adverse effects can be increased when Flupentixol is combined with Alfaxalone. The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Flupentixol. Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol. Degarelix may increase the QTc-prolonging activities of Flupentixol. Trazodone may increase the QTc-prolonging activities of Flupentixol. Metronidazole may increase the QTc-prolonging activities of Flupentixol. Erythromycin may increase the QTc-prolonging activities of Flupentixol. Ofloxacin may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Hexobarbital. The risk or severity of adverse effects can be increased when Flupentixol is combined with Fluspirilene. The risk or severity of adverse effects can be increased when Flurazepam is combined with Flupentixol. Treprostinil may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Canertinib. The risk or severity of adverse effects can be increased when Metoclopramide is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Ritanserin. The risk or severity of adverse effects can be increased when Flupentixol is combined with Baclofen. Flupentixol may decrease the stimulatory activities of Mephentermine. The risk or severity of adverse effects can be increased when Flupentixol is combined with Nitrazepam. The serum concentration of Vincristine can be increased when it is combined with Flupentixol. The risk or severity of adverse effects can be increased when Flupentixol is combined with Levomethadyl Acetate. Droperidol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol. Primaquine may increase the QTc-prolonging activities of Flupentixol. Nicardipine may increase the QTc-prolonging activities of Flupentixol. The risk or severity of adverse effects can be increased when Alprazolam is combined with Flupentixol. Flupentixol may decrease the stimulatory activities of Diethylpropion. Clomipramine may increase the QTc-prolonging activities of Flupentixol. Granisetron may increase the QTc-prolonging activities of Flupentixol. Flupentixol may increase the sedative activities of Pramipexole. The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Domperidone. Flupentixol may decrease the stimulatory activities of Amphetamine. The risk or severity of adverse effects can be increased when Flupentixol is combined with Methoxyflurane. The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Amiodarone.